Heads up , this post is dense, long, and detailed.
--
There is a great thread going, initially about NAC supplement. It veered to Curcumin with Hunter's always knowledgeable influence.
healthunlocked.com/mpnvoice...
Hunter referenced a study, the full version being:
(Study #1, 2009) altmedrev.com/wp-content/up...
I have comments on it below.
I was further motivated to look for some MPN vs Curc studies. This one came up:
(Study #2, 2019) onlinelibrary.wiley.com/doi...
A most compelling argument for Curc. It is not in Vivo (real people) but all studies start in the lab and this safe agent should not require long safety studies.
It is a rare report being very technical but I can reasonably follow. I've found this is a sign of a better quality study, and it further notes consistent results with prior work, a good sign. It also meets my arbitrary cutoff of 2017 for freshness in MPN work.
Likely there are or will be clinical trials going on like the current NAC trial we know about. Any links are welcome. I am inclined to start Curc supp.
Here are my comments, 1st study #1, then the newer study #2.
--
Curcumin study #1 from 2009
The complete report noted by Hunter is:
altmedrev.com/wp-content/up...
Some comments on it.
Curc needs added agents for bioavaility. The product Hunter is using claims "up to 46x greater absorption" showing the subject is being addressed by supp makers, esp since this date of 2009.
<<Because of curcumin’s rapid plasma clearance and conjugation, its therapeutic usefulness has been somewhat limited, leading researchers to investigate the benefits of complexing curcumin with other substances to increase systemic bioavaility>>
--
Some of the anti-inflammatory effects are relevant to molecules also noted with NAC, one example is TNF alpha, so they may share some similar benefits. However NAC and Curc operate differently, so you will be doing something different between these supps:
nutritionandmetabolism.biom...
<< Both curcumin, a component of the spice turmeric, and N-acetylcysteine (NAC), an antioxidant, inhibit activation of NF-κB by inflammatory stimuli, albeit by different mechanisms>>
--
Rheumatoid arthritis
In rats << Intraperitoneal injection of an extract containing 4 mg total curcuminoids/kg/day for four days prior to arthritis induction significantly inhibited joint inflammation in both the acute (75%) and chronic (68%)
phases.>>
Hunter has found this real benefit.
Osteoarthritis
Similarly, member riteandscooter1 has found a benefit for osteoarthritis. <<Assessment every two weeks during the study demonstrated significant
improvements in pain severity (p<0.001) and disability scores (p<0.05)>> This was on real people, but included other supps in the formula so << Curcumin’s role in this improvement cannot be confirmed due to the other botanicals
and zinc in the treatment compound>>
I try to test one supp at a time if possible.
--
Cancer
<< The impact of curcumin’s anti-inflammatory effects on carcinogenesis in humans remains to be determined. However, animal research demonstrates inhibition at all three stages of carcinogenesis – initiation, promotion, and progression>>
<< Currently there are nine ongoing clinical trials investigating the benefits of curcumin as a therapy for various cancers>> Note again the old 2009 date, there should be some results.
--
Safe Dose
<<In every published clinical trial, curcumin appears to be extremely safe, even at doses up to 8 g daily>>
--
Curc may affect certain chemo drugs, both + and -. This could be relevant to HU, but it is not called out here. My guess is any issue would show up in blood counts.
--
Conclusion
<< The primary obstacle to utilizing curcumin therapeutically has been its limited systemic bioavailability>>
It seems this has been addressed with current formulas, but details matter which one you get. Both Hunter and ritaandscooter1 have selected their preferred options.
----------------------------------
Study #2
A study specific to what we care about and full of neat stuff:
onlinelibrary.wiley.com/doi...
This study used MPN patient blood samples.
<< Previous studies showed that curcumin can suppress JAK2/STAT signalling pathways in different type of cancer and injuries.>>
A new target for MPN therapy addressed by Curc:
<< recent studies identified the role of mTOR pathway in MPNs… This pathway has been found deregulated particularly in megakaryocytes of MPNs patients >>
<< curcumin was able to dissociate Raptor from mTOR …Our results suggest that curcumin inhibits proliferation and activates cell death program by modulating JAK2/STAT and mTORC1 pathways >>
I don’t know these details, but we now know to care about mTOR and Curc is showing good effects on mTOR.
--
There are references to HEL cells throughout, I think these are a type of research cell used since the 80’s for various experiments.
--
To my understanding, it had a dramatic effect of killing (apoptosis) bad Jak2 cells. See Figure 1 here. At higher Curc doses most bad cells are dead (Fig. 1B) .
<< This data confirmed the FACS analysis and indicated that curcumin induced apoptosis in a dose-dependent manner in JAK2 V617F-mutated cell line>>
--
Curc is really good to inhibit, or even stop, the STAT pathways that make trouble in MPN:
<< we observed that phosphorylation of STAT5 was 60% reduced, while STAT3 was extremely sensitive to curcumin-mediated JAK2 inhibition and its phosphorylation decreased to 20% even at the lower curcumin dose and was completely blocked at higher concentrations>>
A good actor (SOCS-1 and 3) is enhanced by Curc, being increased by up to 7 times (SOCS-1) and doubled (SOCS-3):
<< Furthermore, the protein expression of SOCS-1 and SOCS-3, negative regulators of JAK/STAT pathway, resulted clearly up-regulated after curcumin treatment>> They confirmed this result at least two ways.
--
The newly MPN relevant pathway mTORC1:
My minimal understanding is Curc can stop this mTORC problem entirely at high enough doses:
<< Our results indicated that curcumin affects the principal modulator of mTORC1: AKT… its (mTORC’s) principal activator PDK was inhibited by low dose curcumin and it appeared unphosphorylated at the maximum concentration utilized>>
--
They tested Curc in samples from real MPN patients to compare to the HEL cell sample tests. << The results were in accordance with in vitro analysis (HEL cells) …These results suggest that curcumin treatment affects JAK/STAT pathway and induces apoptosis in cells from JAK2 V617F mutated patients.>> In Fig. 4, (see Reply below for this figure) the tall black bar lower right shows an obvious, if complicated, effect of Curc on Jak2.
--
Conclusions, Discussion
This study is new and worth our attention:
<< the effects of this phytochemical (Curc) on JAK2-mutated cells have been poorly studied until now.>>
Results are consistent with prior work, this is always a good thing:
<< Our data are in accordance to what has been already published by Chen and colleagues>>
Also consistent with prior studies << we showed that curcumin strongly inhibited the proliferation and induced apoptosis in a dose and time-dependent manner in HEL cells. Furthermore, we found that curcumin markedly reduced JAK2 phosphorylation and, consequently, the activation of its downstream effectors STAT3 and STAT5 in HEL cells>>
**Rux resistance, this is interesting, Curc might help Rux resistance by inhibiting one of the trouble makers << These small kinases (PIM 1-3) are known to be involved in leukemogenesis and in ruxolitinib resistance in MPNs cells>>
Another example of consistent and good results re the newly relevant mTORC:
<< In agreement with the results obtained by Beevers et al in human rhabdomyosarcoma cells, our results in HEL cells showed that curcumin negatively regulated the mTORC1 complex formation… This data are in accordance with the hypothesis that mTORC1 is a JAK2 downstream pathway and it is involved in MPNs pathogenesis >>
Further evidence of good effects << The curcumin effect was strengthened by the observation that CD177, an antigen over expressed in neutrophils of the majority of MPNs patients, was down-regulated by curcumin>>
--
More discussion of Rux limitations (certain bad cells don't rely just on Jak2 allele) and potential Curc benefit for Rux:
<< Ishida et al demonstrated that HEL cells are only partially dependent on JAK2 V617F for survival and this may explain the very limited effect of ruxolitinib and its inefficiency to eradicate JAK2-mutated clone in MPNs patients… curcumin affects both proliferation and survival of HEL cells, suggesting that its role in MPNs could be more effective in blocking neoplastic cells with respect to the common JAK2 inhibitors, such as ruxolitinib >>
--
Prior mTORC inhibitors are useful but have side effects, Curc might do the same thing without these effects
<< mTORC1 inhibitors can cause numerous side effects that could prevent their use. In contrast, curcumin turned out to be safe and non-toxic in many different trials so its use for MPNs treatment could represent an excellent alternative to common mTORC1 inhibitors >>
--
<< this study showed that curcumin exerts an antitumor effect on human JAK2-mutated cells by inducing apoptosis and inhibition of proliferation, through the regulation of both JAK2/STAT and mTORC1 pathways. These findings suggest that curcumin seems to be a promising nutraceutical compound that should be further evaluated in different pharmaceutical formulation for the treatment of MPNs.>>